OCA
TVTX icon

OpenArc Corporate Advisory’s Travere Therapeutics TVTX Stock Holding History

OpenArc Corporate Advisory’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$921K Hold
31,000
– – 0.01% 334
2025
Q4 		$1.18M Buy
+31,000
New +$1.01M 0.02% 282

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

OpenArc Corporate Advisory's TVTX Position: Q1 2026 in Review

OpenArc Corporate Advisory held its Travere Therapeutics (TVTX) position steady in Q1 2026 at 31,000 shares worth $921K. The position accounts for 0.01% of the portfolio, ranked #334.

OpenArc Corporate Advisory first reported a position in TVTX in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.18M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • OpenArc Corporate Advisory held 31,000 shares of Travere Therapeutics worth $921K as of Q1 2026.
  • OpenArc Corporate Advisory left its Travere Therapeutics share count unchanged in Q1 2026.
  • Travere Therapeutics made up 0.01% of OpenArc Corporate Advisory's portfolio in Q1 2026, its #334 holding.
  • OpenArc Corporate Advisory first reported a position in Travere Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • OpenArc Corporate Advisory's Travere Therapeutics position peaked at $1.18M in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on OpenArc Corporate Advisory's 13F filing for Q1 2026, filed 11 May 2026.